Research progress on the pharmacological mechanism, in vivo metabolism and structural modification of Erianin - 22/03/24

Abstract |
Erianin is an important bibenzyl compound in dendrobium and has a wide spectrum of pharmacological properties. Since Erianin was discovered, abundant results have been achieved in the in vitro synthesis, structural modification, and pharmacological mechanism research. Researchers have developed a series of simple and efficient in vitro synthesis methods to improve the shortcomings of poor water solubility by replacing the chemical structure or coating it in nanomaterials. Erianin has a broad anti-tumor spectrum and significant anti-tumor effects. In addition, Erianin also has pharmacological actions like immune regulation, anti-inflammatory, and anti-angiogenesis. A comprehensive understanding of the synthesis, metabolism, structural modification, and pharmacological action pathways of Erianin is of great value for the utilization of Erianin. Therefore, this review conducts a relatively systematic look back at Erianin from the above four aspects, to give a reference for the evolvement and further appliance of Erianin.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Erianin, an extract of Dendrobium officinale, has anti-tumor effects on multiple common tumors of the body. |
• | The anti-cancer effect of Erianin is mainly through promoting tumor cell apoptosis and inhibiting proliferation in many ways. |
• | Erianin has poor water solubility, its drug delivery can be achieved by encapsulating or conjugating it with nanomaterials. |
Abbreviations : AKT, ATG5, ATR, αKG, Bcl-2, Bim, CAMs, CDK, cdc25c, cdc2, cGMP, Chk2, COX-2, CRAF, Cyto-C, DDSs, DFO, DR, DR5, DREAM, ECM, EMT, ERα, ERK1/2, ERS, FADD, FasL, FTO, GSH, GSK-3β, HIF-1α, HRAS, HRVECs, HuRCSCs, IDO, IKKα/β, JAK, JNK, Keap1, LP, MAPK, Mcl-1, MDR, MDM2, METTL3, MEK, MMPs, MSN, mTOR, mTORC1, MTF, m6A, NAC, NF-κB, NLRP3, Nrf2, OAA, PARP, PC, PDK1, PDK2, PFDTES, P-gp, PI3K, PKG, PLK1, PPT1, RAF, RAS, RhoA, RIP, RNA pol II, ROS, ROCK1, S. aureus, SLN, SOD, SrtA, STAT, TBHQ, TCA, TCM, TF, TFE3, TIMP1/2, TLR, TPGS, TRADD, TRAF2, UC, VEGF, 4EBP1, 5-FU
Keywords : Erianin, Synthesis, Metabolism, Structural modification, Pharmacological effects
Plan
Vol 173
Article 116295- avril 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
